A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer-Reference-Cited by-同舟云学术

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer

Published:2019-05-03 Issue:1 Volume:19 Page:
ISSN:1471-2490
Container-title:BMC Urology
language:en
Short-container-title:BMC Urol

Author:

Yoon Sang Eun,Kim Youjin,Cho Jangho,Kang Minyong,Sung Hyun Hwan,Jeon Hwang Gyun,Jeong Byoung Chang,Seo Seong Il,Jeon Seong Soo,Lee Hyun Moo,Choi Han Yong,Lee Su Jin,Park Se Hoon^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12894-019-0463-7.pdf

Reference19 articles.

1. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.

2. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355(9214):1491–8.

3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

5. Joly F, Tannock IF. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol. 2004;15(11):1582–4.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice;Yonsei Medical Journal;2023

2. Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer;Clinical Genitourinary Cancer;2022-08

3. A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer;BMC Cancer;2021-11-29

4. Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series;Journal of Oncology Pharmacy Practice;2021-04-15

5. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer;Prostate Cancer;2020-12-16